术前同步放化疗后yp0—Ⅰ期直肠癌预后分析

doi:10.3760/cma.j.issn.1004-4221.2017.03.010

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (819 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract

Objective To determine the prognostic factors in patients with stage yp0-I rectal cancer following preoperative concurrent chemoradiotherapy. Methods Eighty-seven patients who received preoperative concurrent chemoradiotherapy and total mesorectal excision (TME) for stage yp0-I rectal cancer from January 2008 to December 2013 were enrolled into the present study. TME was performed 4-8 weeks after the concurrent chemoradiotherapy (CRT). Whole pelvic radiotherapy was given at a dose of 45.0-50.4 Gy, along with concurrent chemotherapy using capecitabine or capecitabine combined with oxaliplatin. Local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were calculated using the Kaplan-Meier method, and compared by the Logrank test. Univariate and multivariate prognostic analyses were performed using the Logrank test and the Cox model, respectively. Results The median interval between preoperative CRT and TME surgery was 51 days. Approximately 45% of the patients received adjuvant chemotherapy following TME. The 3-year LRFS, DMFS, DFS, and OS were 98%, 93%, 93%, and 96%, respectively. The multivariate prognostic analysis showed that the downstaging depth score (DDS), which is based on the pre-treatment clinical stage and postoperative pathological stage, was correlated with DMFS and DFS (P=0.020 and 0.005, respectively). The area under the receiver operating characteristic curve of DDS for predicting 3-year DFS was 0.803 at a cut-off value of 5 points. Conclusions Satisfactory long-term survival is achieved in patients with yp0-I stage rectal cancer after preoperative CRT, and DDS can be used as a prognostic factor for long-term survival.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Ning
	Jin Jing
	Yu Jing
	Li Shuai
	Tang Yuan
	Ren Hua
	Liu Wenyang
	Wang Weihu
	Wang Shulian
	Liu Yueping
	Song Yongwen
	Fang Hui
	Liu Xinfan
	Yu Zihao
	Li Yexiong

Key words：　Rectal neoplasms/chemoradiotherapy Neoplasm stage Prognosis
Fund program:National Natural Science Foundation of China (81272510)

Received: 04 November 2016

Corresponding Authors: Jin Jing,Email:jingjin1025@163.com

Cite this article:

Li Ning,Jin Jing,Yu Jing et al. Prognostic factors in patients with stage yp0-I rectal cancer after preoperative concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(3): 296-301.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2017.03.010 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2017/V26/I3/296

[1] Al B,Benson I,National Comprehensive Cancer Networks (NCCN)(2015).NCCN practice guidelines for rectal cancer[EB/OL].2015[2016-10-20].http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf.
[2] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J].N Engl J Med,2004,351(17):1731-1740.DOI:10.1056/ NEJMoa040694.
[3] Bosset JF,Collette L,Calais G,et al. Chemotherapy with preoperative radiotherapy in rectal cancer[J].N Engl J Med,2006,355(11):1114-1123.DOI:10.1056/NEJMoa060829.
[4] Das P,Skibber JM,Rodriguez-Bigas MA,et al. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer[J].Cancer,2007,109(9):1750-1755.DOI:10.1002/cncr.22625.
[5] Fokas E,Liersch T,Fietkau R,et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited:updated results of the CAO/ARO/AIO-94 trial[J].J Clin Oncol,2014,32(15):1554-1562.DOI:10.1200/JCO.2013.54.3769.
[6] Vecchio FM,Valentini V,Minsky BD,et al. The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer[J].Int J Radiat Oncol Biol Phys,2005,62(3):752-760.DOI:10.1016/j.ijrobp.2004.11.017.
[7] Mandard AM,Dalibard F,Mandard JC,et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J].Cancer,1994,73(11):2680-2686.DOI:10.1002/1097-0142.
[8] Valentini V,van Stiphout RGPM,Lammering G,et al. Nomograms for predicting local recurrence,distant metastases,and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials[J].J Clin Oncol,2011,29(23):3163-3172.DOI:10.1200/JCO.2010.33.1595.
[9] Hartley A,Ho KF,McConkey C,et al. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer:analysis of phase Ⅱ/Ⅲ trials[J].Br J Radiol,2005,78(934):934-938.DOI:10.1259/bjr/86650067.
[10] 肖琴,金晶,李晔雄,等.局部晚期中低位直肠癌奥沙利铂联合卡培他滨术前同期放化疗的疗效分析[J].中华放射肿瘤学杂志,2014,23(2):99-103.DOI:10.3760/cma.j.issn.1004-4221.2014.02.005.
Xiao Q,Jin J,Li YX,et al. The effect of oxaliplatin plus capecitabine in combination with radiation for locally advanced lower or middle sited rectal carcinoma[J].Chin J Radiat Oncol,2014,23(2):99-103.DOI:10.3760/cma.j.issn.1004-4221.2014.02.005.
[11] Maas M,Nelemans PJ,Valentini V,et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer:a pooled analysis of individual patient data[J].Lancet Oncol,2010,11(9):835-844.DOI:10.1016/S1470-2045(10)70172-8.
[12] Valentini V,van Stiphout RGPM,Lammering G,et al. Selection of appropriate end-points (pCR vs. 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer[J].Radiother Oncol,2015,114(3):302-309.DOI:10.1016/j.radonc.2015.02.001.
[13] Mansmann UR,Laubender RP.Methodologic diligence is needed to define and validate tumor-size response metrics to predict overall survival in first-line metastatic colorectal cancer[J].J Clin Oncol,2013,31(34):4373-4374.DOI:10.1200/JCO.2013.51.2954.
[14] Heinemann V,von Weikersthal LF,Decker T,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(10):1065-1075.DOI:10.1016/S1470-2045(14)70330-4.
[15] Piessevaux H,Buyse M,De Roock W,et al. Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial)[J].Ann Oncol,2009,20(8):1375-1382.DOI:10.1093/annonc/mdp011.
[16] Heinemann V,Stintzing S,Modest DP,et al. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)[J].Eur J Cancer,2015,51(14):1927-1936.DOI:10.1016/j.ejca.2015.06.116.
[17] de Campos-Lobato LF,Stocchi L,da Luz Moreira A,et al. Downstaging without complete pathologic response after neoadjuvant treatment improves cancer outcomes for cⅢ but not cⅡ rectal cancers[J].Ann Surg Oncol,2010,17(7):1758-1766.DOI:10.1245/s10434-010-0924-4.
[18] George TJ Jr,Allegra CJ,Yothers G.Neoadjuvant rectal (NAR) score:a new surrogate endpoint in rectal cancer clinical trials[J].Curr Colorectal Cancer Rep,2015,11(5):275-280.DOI:10.1007/s11888-015-0285-2.
[19] Neri E,Guidi E,Pancrazi F,et al. MRI tumor volume reduction rate vs. tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy[J].Eur J Radiol,2015,84(12):2438-2443.DOI:10.1016/j.ejrad.2015.08.008.
[20] Li N,Dou LZ,Zhang YM,et al. The use of sequential endorectal US to predict the tumor response of preoperative chemo-radiotherapy in rectal cancer[J].Gastrointest Endosc,2016.DOI:10.1016/j.gie.2016.06.042.
[21] Collette L,Bosset JF,den Dulk M,et al. Patients with curative resection of cT_3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy:does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group[J].J Clin Oncol,2007,25(28):4379-4386.DOI:10.1200/JCO.2007.11.9685.
[22] Breugom AJ,Swets M,Bosset JF,et al. Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer:a systematic review and meta-analysis of individual patient data[J].Lancet Oncol,2015,16(2):200-207.DOI:10.1016/S1470-2045(14)71199-4.
[23] Park IJ,Kim DY,Kim HC,et al. Role of adjuvant chemotherapy in ypT_0-2N₀ patients treated with preoperative chemoradiation therapy and radical resection for rectal cancer[J].Int J Radiat Oncol Biol Phys,2015,92(3):540-547.DOI:10.1016/j.ijrobp.2015.02.020.